March 2026 ASX Announcement UNMARKETABLE PARCEL SALE FACILITY Alterity Therapeutics Limited (ASX:ATH) (ATH or the Company ) announced today that it has established an opt-out unmarketable parcel sale facility ( Facility)

UNMARKETABLE PARCEL SALE FACILITY

Alterity Therapeutics Limited

(ASX:ATH) (ATH or the Company) announced today that it has established an opt-out unmarketable parcel sale facility (Facility)

for shareholders who hold less than $500 worth of fully paid ordinary shares in the Company (Unmarketable Parcel). The Company

has established the Facility for the following reasons:

In accordance with the Company's

Constitution and ASX Listing Rules, the attached letter and Share Retention Form will be sent to all shareholders holding an Unmarketable

Parcel as at the Record Date.

Shareholders with an Unmarketable

Parcel who wish to retain their shareholding need to give the Company written notice by returning the Share Retention Form by no later

than 7.00pm (AEST) on Friday 24 April or acquire additional shares prior to that time such that their holdings comprise a marketable parcel,

otherwise their shares will be sold by the Company.

Shareholders wishing to take advantage of the Facility

and have their shares sold by the Company do not need to take any action.

A summary of key dates in relation to the Facility are as

Documentation in relation to the Facility will shortly

be sent to all shareholders who held an Unmarketable Parcel of shares on the Record Date.

The Company may modify these dates or suspend of terminate

the Facility. Any modification, suspension or termination will be notified to shareholders by way of a market announcement on ASX.

Therapeutics Limited ACN 080 699 065

14, 350 Collins Street, Melbourne, Victoria 3000 Australia

is not licensed to provide financial product advice. The Company makes no recommendation as to whether you should participate in the Facility.

You are encouraged to seek advice from your legal, financial, taxation or other professional advisor if you are unsure about what to do

in response to this notice.

The attached Information Sheet

provides further information about the Facility. If you have any further questions about the Facility, please contact Automic's

Information Line on:

1300 288 664, Overseas: +61 2 9698 5414 or email to hello@automicgroup.com.au

Therapeutics Limited ACN 080 699 065

14, 350 Collins Street, Melbourne, Victoria 3000 Australia

UNMARKETABLE PARCEL SALE FACILITY - DISPOSAL

We are writing to advise you that Alterity Therapeutics

Limited (ASX:ATH) (Company) has established an unmarketable parcel sale facility (Facility) for shareholders who hold less

than $500 in value of fully paid ordinary shares in the Company (Shares) (Unmarketable Parcel) as at 7.00pm (AEST) on 9

March 2026 (Record Date).

The Company is providing this

Facility to assist holders of Unmarketable Parcels who might otherwise find it difficult to sell their Shares without incurring brokerage

or handling costs, due to the size of their holdings.

Holders of Unmarketable Parcels may opt out

of the Facility as noted below.

Our registry records show that you held an Unmarketable

Parcel of less than 62,500 Shares in the Company, based on the Company's closing price (Sale Price) for Shares on the Record

In accordance with clause 2.7(a) of the Company's

constitution (Constitution), if you hold Shares in a CHESS Holding and they remain in a CHESS Holding after 7.00pm (AEST) on Friday,

24 April 2026 (Closing Date), the Company may, without further notice, remove those Shares from the CHESS Holding to an Issuer

Sponsored Holding for the purposes of divestment in accordance with this notice.

The Company will pay all costs

of the sale for holders of an Unmarketable Parcel who use this Facility, excluding tax consequences from the sale which remain the shareholder's

responsibility. In accordance with clause 2.7(b) of the Constitution, the Company may sell Shares under the Facility on the terms and

in the manner which the Company's Directors consider appropriate. You will receive your pro rata share of the proceeds of the sale

of all Shares sold under the Facility, without any deduction for brokerage or handing costs.

As the Company has determined that all payments

to shareholders are to be made via direct credit to their nominated bank account, please ensure your account details are up to date with

the Company's share registry, Automic Pty Ltd (Automic). You can update your banking and personal details by logging in

or registering via the Automic Investor Portal at: https://portal.automic.com.au/investor/home . If you require further assistance, please

contact Automic on Australia: 1300 288 664 Overseas: +61 2 9698 5414.

What do you need to do if you wish to sell

your Unmarketable Parcel?

In accordance with clause

2.7(a) of the Constitution, if you wish to sell your Unmarketable Parcel you do not need to take any action. Your

Shares will be sold through the Facility after the Closing Date and the proceeds of the sale paid to you in accordance with the timetable

If you have previously provided

the Company with details of an account with an Australian financial institution, your sale proceeds will be paid in Australian dollars

by direct credit into that account. The Company encourages you to notify it of your account details by logging in or registering via the

Automic Investor Portal at: https://portal.automic.com.au/investor/home.

Therapeutics Limited ACN 080 699 065

14, 350 Collins Street, Melbourne, Victoria 3000 Australia

What do you need to do if you wish to retain your Unmarketable

In accordance with clause 2.7(a)(iv) of the Constitution,

should you wish to retain your Shares you must:

Pursuant to clause 2.7(a)(iv)

of the Constitution, if the Company has not received a Share Retention Form with respect to your Shares, or your holding has not increased

to at least 62,500 Shares, as at the Closing Date, you will be deemed to have irrevocably appointed the Company as your agent to sell

or otherwise dispose of your Shares under the Facility and to deal with the proceeds of the sale as contemplated above.

A summary of key dates in relation to the Facility are

The Company may modify these

dates or suspend or terminate the Facility. Any modification, suspension or termination will be notified to shareholders by way of a market

announcement on ASX.

The Company is not licensed to

provide financial product advice. The Company makes no recommendation as to whether you should participate in the Facility. You are encouraged

to seek advice from your legal, financial, taxation or other professional adviser if you are unsure about what to do in response to this

The attached Information Sheet

provides further information about the Facility. If you have any further questions about the Facility, please contact Automic's

Information Line on:

Australia: 1300 288 664, Overseas: +61 2 9698 5414 or email

to hello@automicgroup.com.au

Therapeutics Limited ACN 080 699 065

14, 350 Collins Street, Melbourne, Victoria 3000 Australia

INFORMATION SHEET - UNMARKETABLE PARCEL SALE

Why is the Company Implementing the Facility?

The Company welcomes the support

of all shareholders, however, the administrative costs in producing and distributing shareholder communications and maintaining small